Oligodendrocytes, the Forgotten Target of Gene Therapy
Cells · 28.11.2024 · 13 (23) · 1973
DOI: 10.3390/cells13231973 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 28.11.2024. Verfasst von Yasemin Ozgür-Gunes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Oligodendroglia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 430 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Neuratris, Therapy Design Consulting.
Abstract (Originalsprache)
If the billions of oligodendrocytes (OLs) populating the central nervous system (CNS) of patients could express their feelings, they would undoubtedly tell gene therapists about their frustration with the other neural cell populations, neurons, microglia, or astrocytes, which have been the favorite targets of gene transfer experiments. This review questions why OLs have been left out of most gene therapy attempts. The first explanation is that the pathogenic role of OLs is still discussed in most CNS diseases. Another reason is that the so-called ubiquitous CAG, CBA, CBh, or CMV promoters—widely used in gene therapy studies—are unable or poorly able to activate the transcription of episomal transgene copies brought by adeno-associated virus (AAV) vectors in OLs. Accordingly, transgene expression in OLs has either not been found or not been evaluated in most gene therapy studies in rodents or non-human primates. The aims of the current review are to give OLs their rightful place among the neural cells that future gene therapy could target and to encourage researchers to test the effect of OL transduction in various CNS diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
- MIRCen Institute, Laboratoire des Maladies Neurodégénératives, Commissariat à l'Energie Atomique, 92260 Fontenay-aux-Roses, France.
- NEURATRIS at MIRCen, 92260 Fontenay-aux-Roses, France.
- UMR1195 Inserm and University Paris Saclay, 94270 Le Kremlin-Bicêtre, France.
- Therapy Design Consulting, 94300 Vincennes, France.
ORCID-Profile: Yasemin Ozgür-Gunes
Förderung
- Neuratris
- Therapy Design Consulting
Zitieren
APA
Ozgür-Gunes, Y., Le Stunff, C., & Bougnères, P. (2024). Oligodendrocytes, the Forgotten Target of Gene Therapy. Cells, 13(23), 1973. https://doi.org/10.3390/cells13231973
Vancouver
Ozgür-Gunes Y, Le Stunff C, Bougnères P. Oligodendrocytes, the Forgotten Target of Gene Therapy. Cells. 2024;13(23):1973. doi:10.3390/cells13231973
BibTeX
@article{OzgrGunes2024,
author = {Ozgür-Gunes, Yasemin and Le Stunff, Catherine and Bougnères, Pierre},
title = {Oligodendrocytes, the Forgotten Target of Gene Therapy},
journal = {Cells},
year = {2024},
volume = {13},
number = {23},
pages = {1973},
doi = {10.3390/cells13231973}
}
EUVIMED